DPP-4 inhibitors for treating T2DM - hype or hope? an analysis based on the current literature

Kunika Saini; Smriti Sharma; Yousuf Khan

doi:10.3389/fmolb.2023.1130625

DPP-4 inhibitors for treating T2DM - hype or hope? an analysis based on the current literature

Front Mol Biosci. 2023 May 23:10:1130625. doi: 10.3389/fmolb.2023.1130625. eCollection 2023.

Authors

Kunika Saini¹, Smriti Sharma¹, Yousuf Khan¹

Affiliation

¹ Molecular Modelling and Drug Design Laboratory, Department of Chemistry, University of Delhi, New Delhi, India.

Abstract

DPP-4 inhibition is an interesting line of therapy for treating Type 2 Diabetes Mellitus (T2DM) and is based on promoting the incretin effect. Here, the authors have presented a brief appraisal of DPP-4 inhibitors, their modes of action, and the clinical efficiency of currently available drugs based on DPP-4 inhibitors. The safety profiles as well as future directions including their potential application in improving COVID-19 patient outcomes have also been discussed in detail. This review also highlights the existing queries and evidence gaps in DPP-4 inhibitor research. Authors have concluded that the excitement surrounding DPP-4 inhibitors is justified because in addition to controlling blood glucose level, they are good at managing risk factors associated with diabetes.

Keywords: (GLP)-1; DPP-4 enzyme; DPP-4 inhibitors; T2DM; incretin effect; insulin.

Publication types

Review